Drug Interaction Warning Issued for Experimental Breast Cancer Treatment

Researchers have identified a significant drug-drug interaction between itraconazole, a common antifungal, and vepdegestrant, an experimental estrogen receptor degrader in development. The finding could affect dosing protocols and patient safety monitoring as the cancer drug advances through clinical trials and toward potential regulatory approval.

Originaltitel: Letter to the Editor Regarding “The Effect of Itraconazole on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera Estrogen Receptor Degrader, in Healthy Adult Participants” Recently Published by Tran and Colleagues